Goldman Sachs Recommends Non-AI Stock Investments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: CNBC
- Market Trend Analysis: Goldman Sachs highlights that despite the dominance of AI trades pushing the S&P 500 and Nasdaq to multiple record highs this year, there are still noteworthy non-AI companies to invest in, indicating market diversity and potential opportunities.
- Portfolio Recommendations: Goldman analysts suggest a portfolio of Russell 1000 stocks with low sensitivity to both AI trades and economic growth pricing, which have recently seen positive earnings revisions by analysts, indicating fundamental support for these investments.
- Eli Lilly Outlook: Although Eli Lilly's stock has slipped about 1% this year, Goldman believes only 9% of its recent returns are driven by the U.S. economic outlook and AI, while Morgan Stanley's analyst sets a $1,344 price target, implying a 26.2% upside potential.
- Fortinet Strong Performance: Fortinet has surged 68.7% this year, with Goldman attributing 19% of its returns to the U.S. economic outlook and AI; BTIG upgraded its rating to buy with a $125 price target, reflecting confidence in its mid-term revenue growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1064.740
Low
950.00
Averages
1192
High
1500
Current: 1064.740
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharma Company Thrives Due to Innovative Treatments
- Growth Driven by Innovation: The pharma company is experiencing significant growth due to the launch of multiple innovative treatments, with expectations to maintain strong market performance in the coming quarters, further solidifying its leadership position in the industry.
- Strong Stock Performance: As of the afternoon of May 23, 2026, the company's stock price has shown impressive performance, reflecting strong investor confidence in its future growth potential, which may attract more institutional investors.
- Surge in Market Demand: With the introduction of new therapies, market demand for the company's products has surged, expected to drive sales growth of over 20% in the next year, thereby enhancing overall profitability.
- Increased R&D Investment: The company plans to increase its R&D budget by 30% over the next three years to accelerate the development of new drugs, ensuring it maintains a technological edge in the highly competitive pharmaceutical market.
See More
Eli Lilly to Participate in Global Healthcare Conference
- Conference Participation: Eli Lilly will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, where Executive Vice President Kenneth Custer will engage in a fireside chat at 3:20 p.m. Eastern Time, showcasing the company's advancements in cardiometabolic health.
- Live Webcast: The event will feature a live audio webcast available on Lilly's investor website under the 'Webcasts & Presentations' section, ensuring global investors can stay updated on the company's latest developments.
- Replay Availability: A replay of the presentation will be accessible on the same website for approximately 90 days, allowing investors who cannot attend live to access important information, thereby enhancing communication between the company and its investors.
- Company Mission: Eli Lilly is committed to leveraging biotechnology, chemistry, and genetic medicine to tackle significant global health challenges, driving the development of innovative medicines to improve the quality of life for tens of millions, reflecting its leadership in the healthcare sector.
See More
Eli Lilly to Participate in Goldman Sachs Healthcare Conference
- Conference Participation: Eli Lilly will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, where Executive Vice President Kenneth Custer will engage in a fireside chat at 3:20 p.m. Eastern Time, highlighting the company's advancements in cardiometabolic health.
- Live Webcast: The event will feature a live audio webcast available on Lilly's investor website, allowing global investors to access real-time updates on the company's developments, thereby enhancing transparency and investor confidence.
- Mission Reaffirmation: Lilly is committed to leveraging biotechnology, chemistry, and genetic medicine to tackle significant global health challenges, particularly in innovative drug development for diabetes, obesity, and Alzheimer's disease, further solidifying its leadership in the pharmaceutical industry.
- Historical Legacy: With a 150-year history, Eli Lilly has been dedicated to scientific innovation that improves the quality of life for tens of millions of patients worldwide, showcasing its deep-rooted commitment and responsibility in the healthcare sector.
See More
Eli Lilly Returns to Vaccine Market with $4 Billion Acquisition of Three Companies
- Return to Vaccine Market: Eli Lilly announced the acquisition of three vaccine manufacturers for nearly $4 billion, including $1.5 billion for Curevo, which is developing a shingles vaccine, marking its return to the vaccine and infectious disease sector despite regulatory uncertainties.
- Vaccine Development Potential: Curevo's shingles vaccine demonstrated a lower incidence of side effects in phase 2 trials (7.3% compared to GSK's 33%), which could enhance patient uptake and completion rates, thereby strengthening Lilly's competitive position in the vaccine market.
- Strategic Acquisitions: By acquiring Vaccine Company, Lilly aims to potentially launch the first-ever vaccine for the common virus EBV, which is linked to various serious diseases, presenting significant market potential given that around 95% of adults are infected with the virus.
- Market Opportunity Analysis: Although Lilly did not provide revenue estimates for the new vaccines, considering GSK's Shingrix vaccine generated $4.8 billion in sales in 2025, Lilly's new vaccine products could capture a share of the market, particularly with the shingles vaccine's competitive potential.
See More
Signos Secures $20 Million Funding to Expand Market Presence
- Funding Expansion: Health tech startup Signos announced a $20 million funding round aimed at solidifying its foothold in the GLP-1-driven weight loss market while expanding its partnership with medical device giant Dexcom, reflecting strong market confidence in its offerings.
- Distribution Agreement: This funding includes a new distribution deal with Dexcom to feature Signos' subscription plans on Dexcom's direct-to-consumer site, which is expected to significantly enhance user acquisition and brand visibility, boosting the company's competitiveness in the rapidly growing weight loss market.
- AI Technology Innovation: Signos plans to use the new funding to expand its predictive AI features, such as meal scoring, which monitors how users' dietary choices affect glucose levels in real-time, providing personalized health recommendations to help users achieve sustainable weight loss goals.
- Market Potential: According to JP Morgan, it is estimated that by 2030, around 25 million Americans will be on GLP-1 drugs, and Signos' service can not only complement drug treatments but also serve as a standalone weight loss system, addressing the increasing market demand.
See More
Signos Secures $20 Million Funding and Expands Partnership with Dexcom
- Funding Expansion: Health tech startup Signos announced a $20 million funding round, solidifying its position in the GLP-1-driven weight loss market while expanding its partnership with medical device giant Dexcom, reflecting investor confidence in its growth potential.
- First FDA-Cleared Product: The AI-powered glucose monitoring system developed by Signos is expected to receive FDA clearance in 2025, becoming the first product focused on healthy weight loss, marking a significant innovation breakthrough in health management.
- New Distribution Agreement: This funding round includes a new distribution deal with Dexcom to feature Signos' subscription plans on Dexcom's direct-to-consumer site, which is anticipated to significantly enhance user acquisition and market penetration to meet the rising demand for weight loss solutions.
- AI Feature Expansion: The fresh funding will also be directed towards expanding predictive AI features, such as meal scoring, which helps users predict the impact of specific foods on their glucose levels before consumption, thereby driving behavior change and enhancing user experience and market competitiveness.
See More
Pharma Company Thrives Due to Innovative Treatments
- Growth Driven by Innovation: The pharma company is experiencing significant growth due to the launch of multiple innovative treatments, with expectations to maintain strong market performance in the coming quarters, further solidifying its leadership position in the industry.
- Strong Stock Performance: As of the afternoon of May 23, 2026, the company's stock price has shown impressive performance, reflecting strong investor confidence in its future growth potential, which may attract more institutional investors.
- Surge in Market Demand: With the introduction of new therapies, market demand for the company's products has surged, expected to drive sales growth of over 20% in the next year, thereby enhancing overall profitability.
- Increased R&D Investment: The company plans to increase its R&D budget by 30% over the next three years to accelerate the development of new drugs, ensuring it maintains a technological edge in the highly competitive pharmaceutical market.
See More
Eli Lilly to Participate in Global Healthcare Conference
- Conference Participation: Eli Lilly will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, where Executive Vice President Kenneth Custer will engage in a fireside chat at 3:20 p.m. Eastern Time, showcasing the company's advancements in cardiometabolic health.
- Live Webcast: The event will feature a live audio webcast available on Lilly's investor website under the 'Webcasts & Presentations' section, ensuring global investors can stay updated on the company's latest developments.
- Replay Availability: A replay of the presentation will be accessible on the same website for approximately 90 days, allowing investors who cannot attend live to access important information, thereby enhancing communication between the company and its investors.
- Company Mission: Eli Lilly is committed to leveraging biotechnology, chemistry, and genetic medicine to tackle significant global health challenges, driving the development of innovative medicines to improve the quality of life for tens of millions, reflecting its leadership in the healthcare sector.
See More
Eli Lilly to Participate in Goldman Sachs Healthcare Conference
- Conference Participation: Eli Lilly will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, where Executive Vice President Kenneth Custer will engage in a fireside chat at 3:20 p.m. Eastern Time, highlighting the company's advancements in cardiometabolic health.
- Live Webcast: The event will feature a live audio webcast available on Lilly's investor website, allowing global investors to access real-time updates on the company's developments, thereby enhancing transparency and investor confidence.
- Mission Reaffirmation: Lilly is committed to leveraging biotechnology, chemistry, and genetic medicine to tackle significant global health challenges, particularly in innovative drug development for diabetes, obesity, and Alzheimer's disease, further solidifying its leadership in the pharmaceutical industry.
- Historical Legacy: With a 150-year history, Eli Lilly has been dedicated to scientific innovation that improves the quality of life for tens of millions of patients worldwide, showcasing its deep-rooted commitment and responsibility in the healthcare sector.
See More
Eli Lilly Returns to Vaccine Market with $4 Billion Acquisition of Three Companies
- Return to Vaccine Market: Eli Lilly announced the acquisition of three vaccine manufacturers for nearly $4 billion, including $1.5 billion for Curevo, which is developing a shingles vaccine, marking its return to the vaccine and infectious disease sector despite regulatory uncertainties.
- Vaccine Development Potential: Curevo's shingles vaccine demonstrated a lower incidence of side effects in phase 2 trials (7.3% compared to GSK's 33%), which could enhance patient uptake and completion rates, thereby strengthening Lilly's competitive position in the vaccine market.
- Strategic Acquisitions: By acquiring Vaccine Company, Lilly aims to potentially launch the first-ever vaccine for the common virus EBV, which is linked to various serious diseases, presenting significant market potential given that around 95% of adults are infected with the virus.
- Market Opportunity Analysis: Although Lilly did not provide revenue estimates for the new vaccines, considering GSK's Shingrix vaccine generated $4.8 billion in sales in 2025, Lilly's new vaccine products could capture a share of the market, particularly with the shingles vaccine's competitive potential.
See More
Signos Secures $20 Million Funding to Expand Market Presence
- Funding Expansion: Health tech startup Signos announced a $20 million funding round aimed at solidifying its foothold in the GLP-1-driven weight loss market while expanding its partnership with medical device giant Dexcom, reflecting strong market confidence in its offerings.
- Distribution Agreement: This funding includes a new distribution deal with Dexcom to feature Signos' subscription plans on Dexcom's direct-to-consumer site, which is expected to significantly enhance user acquisition and brand visibility, boosting the company's competitiveness in the rapidly growing weight loss market.
- AI Technology Innovation: Signos plans to use the new funding to expand its predictive AI features, such as meal scoring, which monitors how users' dietary choices affect glucose levels in real-time, providing personalized health recommendations to help users achieve sustainable weight loss goals.
- Market Potential: According to JP Morgan, it is estimated that by 2030, around 25 million Americans will be on GLP-1 drugs, and Signos' service can not only complement drug treatments but also serve as a standalone weight loss system, addressing the increasing market demand.
See More
Signos Secures $20 Million Funding and Expands Partnership with Dexcom
- Funding Expansion: Health tech startup Signos announced a $20 million funding round, solidifying its position in the GLP-1-driven weight loss market while expanding its partnership with medical device giant Dexcom, reflecting investor confidence in its growth potential.
- First FDA-Cleared Product: The AI-powered glucose monitoring system developed by Signos is expected to receive FDA clearance in 2025, becoming the first product focused on healthy weight loss, marking a significant innovation breakthrough in health management.
- New Distribution Agreement: This funding round includes a new distribution deal with Dexcom to feature Signos' subscription plans on Dexcom's direct-to-consumer site, which is anticipated to significantly enhance user acquisition and market penetration to meet the rising demand for weight loss solutions.
- AI Feature Expansion: The fresh funding will also be directed towards expanding predictive AI features, such as meal scoring, which helps users predict the impact of specific foods on their glucose levels before consumption, thereby driving behavior change and enhancing user experience and market competitiveness.
See More
